Study OEV-123 – Phase IIb Safety, diagnostic methodology evaluation and estimated vaccine efficacy in travellers to Benin
A randomised, placebo controlled, double blinded phase 2b study was conducted in 743 Finnish tourists, between the ages of 18 to 65 years of age, travelling to Benin. The objectives were to evaluate safety and tolerability, new diagnostical methodology and establish preliminary vaccine efficacy. The results were unblinded in 2020 and confirmed the excellent safety and overall positive immunogenicity of ETVAX®. Read more here.
This study is co funded by SME Instrument, part of the EU’s Horizon 2020 research and Innovation programme.
Studies
- All studies
-
Study OEV-128 – Phase IIB Study in children 6-18 months in The Gambia
-
Study OEV-124 – Phase I, Age-descending study in Zambia
-
Study OEV-123 – Phase IIb Safety, diagnostic methodology evaluation and estimated vaccine efficacy in travellers to Benin
-
Study OEV-122 – Phase I/II, Age descending safety and immunogenicity trial in Bangladesh (age ≥6 mo)
-
Study OEV-121A – Phase I, Booster dose memory study
-
Study OEV-121 – Phase I, Safety and immunogenicity of vaccine
-
Study OEV-120 – Phase I, Safety and immunogenicity of a prototype vaccine
-
Study DMID 09-066 – Phase I, dmLT adjuvant safety and immunogenicity
-
